BRPI0410951A - nucleotìdeos para prevenção e tratamento de patologias bacterianas e fungicas - Google Patents

nucleotìdeos para prevenção e tratamento de patologias bacterianas e fungicas

Info

Publication number
BRPI0410951A
BRPI0410951A BRPI0410951-1A BRPI0410951A BRPI0410951A BR PI0410951 A BRPI0410951 A BR PI0410951A BR PI0410951 A BRPI0410951 A BR PI0410951A BR PI0410951 A BRPI0410951 A BR PI0410951A
Authority
BR
Brazil
Prior art keywords
ssdna
bacterial
library
odns
prevention
Prior art date
Application number
BRPI0410951-1A
Other languages
English (en)
Inventor
Yin Chen
Xin Xing Tan
Original Assignee
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/453,410 external-priority patent/US20040248101A1/en
Priority claimed from US10/743,956 external-priority patent/US20050136393A1/en
Application filed by Cytogenix Inc filed Critical Cytogenix Inc
Publication of BRPI0410951A publication Critical patent/BRPI0410951A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"NUCLEOTìDEOS PARA A PREVENçãO E O TRATAMENTO DE PATOLOGIAS BACTERIANAS E FUNGICAS". Uma biblioteca da expressão de DNA de fita simples (ssDNA) seletivamente induzível, um método para construir uma biblioteca da expressão de ssDNA, um método para selecionar o ssDNA usando a biblioteca da expressão, e um método para identificar as moléculas do ssDNA que alteram a expressão do gene (s) bacterianos e fúngicos relacionados ao crescimento da célula e à produção e à secreção de toxina. A biblioteca da seleção é usada para, entre outras coisas, identificar os ODNs eficazes em parar o crescimento da célula, em matar bactérias ou fungos, ou em impedir que as bactérias e/ou os fungos sintetizem e secretem suas toxinas, e/ou para descobrir os ODNs eficazes em células de eucarióticos (por exemplo, mamíferos) para a alteração alvo da função do gene. A biblioteca é também útil para identificar os ssDNAs ou o ODNs que são usados como agentes terapêuticos, por exemplo, fornecendo um método para o tratamento de infecções bacterianas, tais como, a sepsis.
BRPI0410951-1A 2003-06-03 2004-06-03 nucleotìdeos para prevenção e tratamento de patologias bacterianas e fungicas BRPI0410951A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/453,410 US20040248101A1 (en) 2003-06-03 2003-06-03 Identification of novel antibacteria agents by screening the single-stranded DNA expression library
US10/743,956 US20050136393A1 (en) 2003-12-23 2003-12-23 Oligodoxynucleotide (ODN) libraries, their use in screening for antibacterial agents, and catalytic ODN sequence for use as an antibacterial agent
US10/818,158 US20050020526A1 (en) 2003-06-03 2004-04-05 Oligodeoxynucleotide intervention for prevention and treatment of sepsis
PCT/US2004/017331 WO2004108840A2 (en) 2003-06-03 2004-06-03 Nucleotides for prevention and treatment of bacterial and fungal pathologies

Publications (1)

Publication Number Publication Date
BRPI0410951A true BRPI0410951A (pt) 2006-07-25

Family

ID=33514683

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410951-1A BRPI0410951A (pt) 2003-06-03 2004-06-03 nucleotìdeos para prevenção e tratamento de patologias bacterianas e fungicas

Country Status (9)

Country Link
US (3) US20050020526A1 (pt)
EP (1) EP1646719A2 (pt)
JP (1) JP2006526416A (pt)
KR (1) KR20060065580A (pt)
AU (1) AU2004245978A1 (pt)
BR (1) BRPI0410951A (pt)
CA (1) CA2528131A1 (pt)
IL (1) IL172324A0 (pt)
WO (1) WO2004108840A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160581A1 (en) * 1994-04-29 2007-07-12 Cytogenix, Inc. Production of ssDNA in vivo
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
US20050260588A1 (en) * 2002-05-01 2005-11-24 Conrad Charles A In vivo ssdna expression vectors for altering gene expression
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
BRPI0516118A (pt) * 2004-09-28 2008-08-26 Cytogenix Inc oligonucleotìdeos de fita simples antimicrobianos e usos dos mesmos
CN103361321B (zh) * 2013-06-27 2015-02-18 华东理工大学 一种ssDNA-蛋白质酶法交联方法
EP2886651B1 (en) * 2013-10-21 2018-08-22 Ajinomoto Co., Inc. Method for producing l-amino acid
CN110242244B (zh) * 2014-03-07 2021-09-07 株式会社吴羽 钻井用堵塞器
US10240427B2 (en) * 2014-07-07 2019-03-26 Halliburton Energy Services, Inc. Downhole tools comprising aqueous-degradable sealing elements
KR101675359B1 (ko) * 2014-12-30 2016-11-14 건국대학교 글로컬산학협력단 네오아가로올리고당을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
WO2016123628A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Colorado, A Body Corporate Sequence specific and organism specific antimicrobials and related materials and methods
US10472918B2 (en) * 2015-10-28 2019-11-12 Halliburton Energy Services, Inc. Degradable isolation devices with embedded tracers
EP3263115A1 (de) * 2016-06-30 2018-01-03 Technische Hochschule Mittelhessen Erfindung betreffend wirkstoff gegen pseudomonas aeruginosa
CN108315452B (zh) * 2018-04-28 2021-02-12 内蒙古农业大学 一种用于肠道中双歧杆菌属定量的引物及定量方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5294533A (en) * 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5436141A (en) * 1989-02-24 1995-07-25 University Of Medicine And Dentistry Of New Jersey Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5843738A (en) * 1990-08-14 1998-12-01 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5442049A (en) * 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5714323A (en) * 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
US6054299A (en) * 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5919677A (en) * 1997-05-09 1999-07-06 The Research Foundation Of State University Of New York Eukaryotic and retroviral antisense initiator elements
US6300318B1 (en) * 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
AU3751299A (en) * 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
AU6298899A (en) * 1998-10-09 2000-05-01 Ingene, Inc. Production of ssdna (in vivo)
AUPP810399A0 (en) * 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
WO2000060115A2 (en) * 1999-04-02 2000-10-12 City Of Hope Method for identifying accessible binding sites on rna
US7419964B2 (en) * 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
MXPA02003422A (es) * 1999-10-04 2004-09-10 Cytogenix Inc Alteracion de la expresion de genes con adnss producido in vivo.
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US20030148352A1 (en) * 2001-12-14 2003-08-07 Yale University Intracellular generation of single-stranded DNA
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
US20050136393A1 (en) * 2003-12-23 2005-06-23 Cytogenix, Inc. Oligodoxynucleotide (ODN) libraries, their use in screening for antibacterial agents, and catalytic ODN sequence for use as an antibacterial agent
US20040248101A1 (en) * 2003-06-03 2004-12-09 Cytogenix, Inc. Identification of novel antibacteria agents by screening the single-stranded DNA expression library
BRPI0516118A (pt) * 2004-09-28 2008-08-26 Cytogenix Inc oligonucleotìdeos de fita simples antimicrobianos e usos dos mesmos

Also Published As

Publication number Publication date
IL172324A0 (en) 2009-02-11
WO2004108840A8 (en) 2005-06-16
US20070020635A1 (en) 2007-01-25
AU2004245978A1 (en) 2004-12-16
JP2006526416A (ja) 2006-11-24
CA2528131A1 (en) 2004-12-16
KR20060065580A (ko) 2006-06-14
US20050020526A1 (en) 2005-01-27
US8889397B2 (en) 2014-11-18
EP1646719A2 (en) 2006-04-19
WO2004108840A2 (en) 2004-12-16
US20150094236A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
Qin et al. Pseudomonas aeruginosa extracellular products inhibit staphylococcal growth, and disrupt established biofilms produced by Staphylococcus epidermidis
Lee et al. Discovery of a widely distributed toxin biosynthetic gene cluster
Ibáñez de Aldecoa et al. Mechanisms and regulation of extracellular DNA release and its biological roles in microbial communities
Antoraz et al. Toward a new focus in antibiotic and drug discovery from the Streptomyces arsenal
Li et al. LPS remodeling is an evolved survival strategy for bacteria
Miwa et al. How effectors promote beneficial interactions
Abrudan et al. Socially mediated induction and suppression of antibiosis during bacterial coexistence
O’Brien et al. An ecological perspective of microbial secondary metabolism
BRPI0410951A (pt) nucleotìdeos para prevenção e tratamento de patologias bacterianas e fungicas
Kim et al. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs
Córdova-Albores et al. Omics sciences potential on bioprospecting of biological control microbial agents: the case of the Mexican agro-biotechnology
Gao et al. Cotesia vestalis teratocytes express a diversity of genes and exhibit novel immune functions in parasitism
Vilcinskas Evolutionary ecology of parasitic fungi and their host insects
Sulaiman et al. Application of proteomics in studying bacterial persistence
Xiao et al. An IMD-like pathway mediates the intestinal immunity to modulate the homeostasis of gut microbiota in Rhynchophorus ferrugineus Olivier (Coleoptera: Dryophthoridae)
Long et al. Mode of action of elasnin as biofilm formation eradicator of methicillin-resistant Staphylococcus aureus
South et al. Identification of predicted seminal fluid proteins in Tribolium castaneum
Cullin et al. Murein hydrolase LytF of Streptococcus sanguinis and the ecological consequences of competence development
Hammad et al. Food safety and biological control; genomic insights and antimicrobial potential of Bacillus velezensis FB2 against agricultural fungal pathogens
Gastélum et al. Interaction networks reveal highly antagonistic endophytic bacteria in native maize seeds from traditional milpa agroecosystems
Dharmaprakash et al. Development of broad-spectrum antibiofilm drugs: strategies and challenges
Gélinas et al. Cellular adaptation and the importance of the purine biosynthesis pathway during biofilm formation in Gram-positive pathogens
Yu et al. Identification of immunity-related genes in Dialeurodes citri against entomopathogenic fungus Lecanicillium attenuatum by RNA-Seq analysis
Heßeler et al. Coexistence in the chemostat as a result of metabolic by-products
Moche et al. Time-resolved analysis of cytosolic and surface-associated proteins of Staphylococcus aureus HG001 under planktonic and biofilm conditions

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.